Accumulating evidence showed that the high expression of LC3B is related to the high aggressiveness and adverse prognosis of many types of cancers, including colorectal cancers (102), breast cancer (103) and hepatocellular carcinoma (104). Here, MAP1LC3B is linked to hepatocellular carcinoma.